Hepatitis C virus (HCV) has become a major cause of morbidity and mortality in HIV-infected individuals.1–3 It has been reported that 20%–30% of HIV-infected individuals are infected with HCV in the United States and worldwide.4,5 Since the introduction of antiretroviral treatment (ART) and pegylated-interferon treatment, ART has led to a significant decrease in HIV-associated disease, but the development of cirrhosis in HIV + patients with longstanding HCV infection continues to increase. Although ART has improved the life expectancy of persons with HIV, coinfected persons survive to at times develop neuropsychological (NP) impairment that can greatly impact their quality of life. Various studies have shown controlled chronic HIV infection that can result in neurocognitive dysfunction. Chronic HCV infection has also been associated with neurocognitive dysfunction, even in the absence of advanced liver damage.6–8 HIV/HCV coinfection has been found in some studies to be associated with impairment in executive9 and psychomotor function,10 and overall cognition.11,12 While some reports did not demonstrate cognitive differences between coinfected and HCV monoinfected subjects, this could be because of the heterogeneous composition of some cohorts, including active HIV infection and various stages of AIDS, drug, or alcohol abuse and the prevalence of cirrhosis. Some studies included HIV+ subjects with high viral load or advanced AIDS, who are fortunately now quite uncommon in the era of ART. AIDS, drug, or alcohol abuse, alone or in combination, have been related to neurocognitive dysfunction.13,14 To minimize the interfering factors and comorbid conditions and in an effort to clarify the effect of HCV on cognitive dysfunction or combined with controlled HIV infection, the current cohort was enrolled that was free of substance abuse, without current clinical depression, and with undetectable HIV viral load. We used an extensive NP battery of tests, including a depression scale, to obtain a better understanding of the impact of HCV among patients with well-controlled HIV who reflect the current use of effective ART treatment.
This is a cross-sectional study of 53 participants recruited from the Gastroenterology clinics at the Veterans Affairs Medical Center, San Francisco and the University of California, San Francisco affiliated hospitals who signed written informed consent for protocols that had been approved by the University of California, San Francisco Committee on Human Research. Determining compatibility with the inclusion and exclusion criteria was based on medical record review for HIV and/or HCV-infected subjects and self-report for the controls. All participants were given minimal compensation for participation that was not disclosed on recruitment flyers. In North America, HCV transmission occurs primarily through shared needles during intravenous drug use, blood transfusions before 1992, body piercings, or tattoos. Among these risk factors, intravenous drug use typically coincides with a history of drug abuse, and there is evidence that the use of psychoactive substances can impair cognition, as such patients' histories of intravenous drug use and other psychoactive substance use were recorded in detail. Inclusion criteria for this study were men between the ages of 45 and 65 years with HCV infection, subjects with HIV/HCV coinfection (HCV genotype 1), or healthy controls. Coinfected subjects were compliant on ART for at least 2 years with undetectable HIV viral load (<50 copies/mL) for 6 months before enrollment. Exclusion criteria included illicit drug use or prescribed opiate pain medications 6 months before enrollment; clinical evidence of hepatic cirrhosis (all patients had either past liver biopsies or imaging studies revealing no cirrhosis); evidence of any other chronic infectious processes; consumption of >20 g alcohol per day for the 6 months before enrollment; IFNα-based therapy within the previous 4 years; clinical depression or other significant psychiatric disease; and seizure disorders or history of head injury. Mood disorders and psychiatric exclusionary diagnosis were defined by a clinical interview by the study psychologist (L.A.), using the Structured Clinical Interview for DSM-IV.15
To compare HCV mono- and coinfected subjects with HIV infection, we included 14 HIV monoinfected individuals with undetectable viral loads along with 11 controls from a previous study published in 2010.16 Subjects in the HIV cohort were recruited from the Infectious Disease clinic at the same Veterans Affairs Medical Center, San Francisco, using the same inclusion/exclusion criteria with the exception of being HIV infected, on ART, with an undetectable (<50 copies/mL) viral load. All the NP testing was performed by the same investigator (L.A.).
NP test measures covered 7 domains. The Structured Clinical Interview for DSM-IV15 was used to establish a lifetime history of depressive illness and to diagnose exclusionary psychiatric disorders. Participants also completed a self-report depression measure, the Beck Depression Inventory (BDI)-II.17 General intellect (estimated intelligence quotient[IQ]) was assessed using the Information subtest from the Wechsler Adult Intelligence Scale—Third Edition.18 NP test results were demographically corrected according to educational level, gender, and age, based on the normative scoring for each test. All individual test scores were converted to standard T scores.
Global Deficit Score
The global deficit score (GDS) is a single number representing overall NP test performances. The T scores from each test were converted to a deficit score based on Carey et al.19 Briefly, ≥40T = 0; 39T–35T = 1; 34T–30T = 2; 29T–25T = 3; 24T–20T = 4; ≤19T = 5. The mean of the deficit scores from each test was assigned to the participant as GDS. A GDS of 0.5–1 was considered mild impairment. As reported previously, we used a GDS of ≥0.5 as neuropsychologically impaired.16
Demographic data were analyzed using nonparametric statistical analyses (Pearson χ2 test) for categorical data and the rates of significant cognitive impairment across groups. One-way analyses of variance were used for continuous data. Since education and IQ showed differences, they were included as covariates in the analyses of BDI, GDS, and all NP tests in the multivariate analysis of variance. A Tukey post hoc test was used to compare group differences after the multivariate analysis of variance. Pairwise comparisons of group means were achieved using Student 2-sample t test for unequal variances (Welch t test) with P values adjusted using Benjamini and Hochberg20 correction for multiple comparisons where necessary. Correlations of NP domains and GDS with plasma HCV RNA levels were analyzed using Spearman rank correlation coefficient due to the distribution nature of the data. The correlation between GDS and BDI was also analyzed using Spearman correlation. All tests were performed with R v18.104.22.168
We enrolled 19 HCV monoinfected individuals (HCV), treatment naive except for 2 treatment failures; 17 HCV-infected individuals with controlled HIV-1 infection (Co); and 17 age-, education- and ethnicity-matched controls (C). Fourteen HIV-infected subjects with undetectable HIV viral load (HIV) and 11 controls from a previous study16,22 were also included for comparison purposes (Table 1). There was no significant difference in HCV plasma viral load between HIV or HCV coinfection and HCV monoinfection (P = 0.31). Also, there was no significant difference in the mean age of the different groups, while the mean education level of controls was approximately 2–2.5 years higher than participants with HCV (P = 0.011), coinfection (P = 0.013), and HIV (P = 0.012) (Table 1). IQ was lower in HIV/HCV coinfected subjects than controls (P = 0.004) and HIV monoinfected subjects (P = 0.025) after adjusting education. HCV monoinfected subjects had lower IQ than controls and HIV monoinfected individuals, but this was not statistically significant (P = 0.098 and 0.260, respectively) after adjusting for education. All HIV-infected participants were on ART16 for over 2 years. All HIV-infected and HIV/HCV-coinfected participants had undetectable plasma HIV viral load at the time of participation (<50 copies/mL). Ethnicity was not a significant variable (χ2 = 6.84, P value = 0.654). No subjects with known cirrhosis were included.
We evaluated participants in the HCV cohort to determine whether exposure to drugs of abuse coincided with lower NP test results. In the HCV group, 63% (12/19) of the participants had a history of drug abuse, whereas 71% (12/17) of the coinfected also had abused drugs. A possible relationship between drug abuse and cognition in either of the mono- or coinfected groups in this study was examined using a Fisher exact test and was found not to be significant among either HCV monoinfected (P = 0.4) or coinfected (P = 1.0) subjects. The controls in the HCV cohort did not report any history of drug abuse. For the HIV cohort, a separate drug abuse history, apart from that collected for compliance with the exclusion criteria, was not obtained and is a limitation of this study.
Because depressive symptoms may still exist in the HCV-infected patients, we used the BDI, a self-report questionnaire, as a screening tool for perceived depression not diagnosed clinically. Coinfected subjects were found to have more depressive symptoms by BDI (11.1 ± 7.5) than controls (5.4 ± 4.1, P = 0.011) (Fig. 1A) and HCV monoinfected subjects (6.7 ± 6.0, P = 0.049), although no subject carried a clinical diagnosis of depression.
A summary of all NP tests measured in the study was represented by a GDS, which reflects the overall cognitive status of the participants. HIV/HCV coinfection had a worse GDS score (0.77 ± 0.74) than HCV monoinfection (0.46 ± 0.34, P = 0.015), HIV monoinfection (0.45 ± 0.36, P = 0.008), or controls (0.30 ± 0.29, P < 0.001) (Fig. 1B). The mean GDS of 0.77 for HIV/HCV puts the coinfected individuals in the mild cognitive impairment range (0.5–1.0).19 The rates of impairment based on GDS were higher in coinfection (65%) than in HCV monoinfection (42%), HIV monoinfection (29%), and controls (18%). Although this difference was not statistically significant among coinfection, HIV monoinfection, or HCV monoinfection (χ2 = 4.2, P = 0.12), coinfection did have a higher rate than controls (χ2 = 8.2, P = 0.004). There was no correlation found between GDS and BDI in HCV-infected individuals (Spearman correlation, rho = 0.13, P = 0.45) suggesting that depression did not influence GDS. Controls from the HIV and HCV cohorts were used in GDS analysis, whereas for depression analysis, only controls from HCV cohort were used because depression analysis was not done on the HIV cohort.
Although the tests were grouped into domains, individual NP tests showed significant differences among groups after adjusting for education and IQ (Table 2). Lower scores were found in Digit Span and Brown-Peterson tests in HIV/HCV coinfected subjects indicating impairment in attention and short-term memory. When considering the domain, subjects with HIV/HCV coinfection demonstrated lower performance in attention/working memory compared with controls (P = 0.006) (Fig. 2). Impairment in Symbol Digit Written test in HIV/HCV coinfection and not in the Symbol Digit Oral test indicates malfunction of psychomotor ability although the information processing speed domain did not show significant difference (Table 2). Although the Stroop Color and Word test showed higher performance in HIV than C, HCV, and coinfection, when considering all 4 tests in the executive function domain, coinfection had lower performance than controls in general (P = 0.026) (Fig. 2). In the Grooved pegboard test, the nondominant hand performed poorer in coinfection than controls (P = 0.035). Fine motor function as a domain was more impaired in coinfected subjects than controls (P = 0.013). In Brief Visuospatial Memory Test and California Verbal Learning Tests, coinfection showed significant impairment in visual learning and memory (P < 0.001) and verbal learning and memory (P < 0.001) than controls (Fig. 2 and Table 2). Despite undetectable HIV, viral loads in both, HIV- and HCV-coinfected individuals showed lower ability on fine motor function (P < 0.001), visual learning/memory (P < 0.001), and verbal learning/memory (P = 0.001) than HIV monoinfected individuals (Fig. 2). HIV/HCV coinfection showed an overall decrease in most of the domains tested (see Figure S1, Supplemental Digital Content, http://links.lww.com/QAI/A369). Subtle deficits can be seen in verbal learning/memory in coinfected patients with T scores nearly 1 SD lower than the population mean. The visual learning/memory domain showed a moderate deficit in coinfection of almost 2SDs below the mean (mean T score = 30.9 ± 10.0).
Although the HCV group did not cross the threshold of cognitive impairment (GDS ≥ 0.5), HCV plasma viral load was negatively correlated with attention, executive function, and information processing speed (Fig. 3A). These relationships were not observed in coinfected subjects, where HCV viral load did not correlate with cognitive performance. The same respective outcomes for HCV mono- and coinfected subjects were found when T scores were switched with GDS as a measure of overall cognition (Fig. 3B). Again, only HCV viral load in the context of monoinfection was related to poorer cognitive performance.
Over the last decade, numerous studies have assessed the impact of HCV monoinfection and HIV/HCV coinfection on cognition. Overall, results from these studies have been inconclusive with some indicating greater cognitive impairment in coinfected individuals, while other studies fail to detect significant difference between mono- and coinfection.11 Potentially there are multiple reasons for this disparity including cohort composition, utilization of different NP assessments, and subtlety of the cognitive dysfunction related to HCV infection. For this cross-sectional study, males under stable medical care who were not abusing drugs were assessed for NP deficits in 7 domains and evaluated for subclinical depression. The study was designed to test for cognitive impairment in coinfected subjects whose HIV was controlled and to measure cognitive dysfunction in HCV-infected subjects with no current drug or alcohol abuse. In fact, this study represents many American HIV-infected individuals today, who are compliant with their ART and live their lives with undetectable HIV viral loads, as did both coinfected and HIV-monoinfected subjects in this study. Moreover, to remove liver dysfunction as a factor influencing cognition, subjects with cirrhosis were excluded from the study. So while this study comprises a limited number of individuals, its strength lies in a well-characterized cohort with minimal comorbid conditions.
Indications are that coinfection in subjects with undetectable HIV viral loads has at most a subtle impact on cognition. By examining a relatively homogeneous cohort of men, all receiving a similar level of medical care, we were able to detect a mild, yet, significant impairment in cognition among the coinfected group. Coinfected subjects performed poorly on the attention, executive function, fine motor function, and visual and verbal learning/memory tests, with significantly lower T scores than either controls or monoinfected subjects. Our results from the male cohort are in contrast to a recent study of coinfected women, which found no association between viral infection and cognition.32 Importantly, in the women's study, only a limited number of NP tests were performed to assess 2 domains: information processing (symbol-digit modalities, Trails part A and B) and executive function (Comalli–Kaplan Stroop test) we also found no differences in these 2 domains. Our more comprehensive evaluation used 20 tests that yielded information for 7 domains. Historically, studies on the impact of HIV on NP function have indicated deficits most consistently in the domain of motor skills, although more recent studies have shown deficits also in attention, executive function, and information processing speed.16 Overall, NP impairment has been reported in a coinfected cohort with deficits in visual and verbal learning/memory domains, which can interfere with daily life.12 HIV-infected individuals subsequently exposed to HCV also have neurocognitive impairment with abnormal brain metabolites ratios.33 We found that both HIV and HCV monoinfected subjects had test results similar to controls in most domains suggesting a synergistic effect of HIV and HCV in coinfection that is responsible for NP deficits in the coinfected population. Previous substance abuse did not correlate with cognitive impairment in the coinfected group. The majority of these individuals were in the military, and by self-report, their substance abuse was related to their youth, and because these subjects were all older than 45 years, the impact of previous substance abuse is probably minimal. However, verification of self-report of participants was not done and therefore a limitation of the study.
Our expectation was that lower cognitive scores in HCV monoinfection would be similar to coinfection, likely affecting the same domains but perhaps less severe. Instead, there was a distinctly different pattern in the NP tests that varied with HCV viral load in monoinfection inversely correlating with T scores in 3 separate domains. Although as a group, cognitive scores did not cross the threshold of impairment, these results suggest that greater HCV viral load negatively impacts cognition. HCV viral load has been investigated as an independent factor influencing cognition in HCV monoinfected individuals, but the results have been equivocal. No association between cognition and viral load was detected when HCV-monoinfected subjects were grouped based on their level of fatigue and secondarily evaluated for viral load.34 However, when evaluated by Spearman rank coefficient analysis, lower T scores in the attention/working memory domain correlated with higher HCV viral load.12 This was one of the same domains affected in our HCV monoinfected subjects, which also showed a significant correlation with lower T scores. Together, these findings imply that HCV viral load may play an important but subtle negative role in cognition, a role that could be better elucidated by experiments specifically designed to assess its impact. The relationship of HCV viral load on NP tests was not detected in coinfected subjects in this study, suggesting that cognitive impairment observed with coinfection could have a different pathogenesis from that in monoinfection. Some studies showed impairment in attention, concentration, and psychomotor speed in HCV infection independent of coinfection.11 The mechanisms for NP impairment in HCV infection are still not well elucidated and may be related to direct HCV viral toxicity, as replicable forms of HCV virus have been detected in autopsy brains.35,36 Brain magnetic resonance spectroscopy studies in HCV infection have also demonstrated inflammation in the brain.37 HCV has been shown to induce microglia activation.38 Brain levels of monocyte chemoattractant protein-1, tumor necrosis factor-α, and soluble tumor necrosis factor receptor were found higher in HCV-infected individuals.12 These observations suggest that HCV is neurotoxic although whether the mechanism is direct or indirect is unknown.
Depression has also been reported to be more severe in coinfection than monoinfection.6 We found the depression scores in coinfection were slightly higher than controls and HCV monoinfection. Elevated BDI scores indicated that coinfected individuals experienced more symptoms of depression but did not meet a clinical depression diagnosis. Importantly, BDI scores did not correlate with NP measures or GDS indicating that depression was not responsible for neurocognitive deficits.
Whether coinfection constitutes a legitimate risk factor for cognition remains to be demonstrated unambiguously. This targeted study indicates that coinfection in males is sufficient to push this group over the threshold into mild impairment and high viral load in HCV monoinfection may impact cognition.
The authors thank their patients for participation and Dorthe Welch, RN, for recruitment.
1. Monto A, Schooley RT, Lai JC, et al.. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol. 2010;105:989–1004; quiz 1988, 1005.
2. Smith C, Sabin CA, Lundgren JD, et al.. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537–1548.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567.
4. Sherman KE, Rouster SD, Chung RT, et al.. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–837.
5. Cargill VA. HIV/hepatitis C virus co-infection: its human face. AIDS. 2005;19(suppl 3):S1–S2.
6. Clifford DB, Evans SR, Yang Y, et al.. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. 2005;19(suppl 3):S64–S71.
7. Forton DM, Thomas HC, Murphy CA, et al.. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–439.
8. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440–446.
9. Ryan EL, Morgello S, Isaacs K, et al.. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology. 2004;62:957–962.
10. von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, et al.. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr. 2004;35:131–137.
11. Perry W, Carlson MD, Barakat F, et al.. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS. 2005;19(suppl 3):S79–S84.
12. Letendre SL, Cherner M, Ellis RJ, et al.. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS. 2005;19(suppl 3):S72–S78.
13. Devlin KN, Gongvatana A, Clark US, et al.. Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc. 2012;18:68–78.
14. Persidsky Y, Ho W, Ramirez SH, et al.. HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun. 2011;25(suppl 1):S61–S70.
15. First M, Spitzer R, Williams J, et al.. Structured Clinical Interview for DSM-IV (SCID-I; Patient Version ed.). New York, NY: New York State Psychiatric Institute, Biometrics Research; 1996.
16. Sun B, Abadjian L, Rempel H, et al.. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol. 2010;16:115–124.
17. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
18. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
19. Carey CL, Woods SP, Gonzalez R, et al.. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307–319.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57:125–133.
21. Ihaka R, Gentleman R. R. A language for data analysis and graphics. J Comput Graph Stat. 1996;5:299–314.
22. Rempel H, Sun B, Calosing C, et al.. Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS. 2010;24:1415–1423.
23. Struss DT, Stethem LL, Poirier CA. Comparison of three tests of attention and rapid information processing across six age groups. Clin Neuropsychol. 1987;1:139–152.
24. Smith A. Symbol Digit Modalities Test (SDMT) Manual. Revised ed. Los Angeles, CA: Western Psychological Services; 1982.
25. Golden CJ. Stroop Color and Work Test. Chicago, IL: Stoelting; 1978.
26. Heaton RK, Chelune GJ, Talley JL, et al.. Wisconsin Cart Sorting Test (WCST) manual. Revised and expanded ed. Odessa, FL: Psychological Assessment Resources; 1993.
27. Klove H. Clinical neuropsychology. In: Foster FM, ed. The Medical Clinics of North America. New York, NY: Saunders; 1963.
28. Halstead W. Brain and Intelligence. Chicago, IL: University of Chicago Press; 1947.
29. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. 3rd ed. Iowa City, IA: AJA Associates; 1983.
30. Benedict RH. Brief Visuospatial Memory Test - Revised (BVMT-R). Odessa, FL: Psychological Assessment Resources, Inc; 1997.
31. Delis DC, Kaplan E, Kramer JH, et al.. California Verbal Learning Test – Second Edition (CVLT-II). San Antonio, TX: The Psychological Corporation; 1987.
32. Crystal H, Kleyman I, Anastos K, et al.. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2012;59:149–154.
33. Winston A, Garvey L, Scotney E, et al.. Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? J Viral Hepat. 2010;17:419–426.
34. McAndrews MP, Farcnik K, Carlen P, et al.. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005;41:801–808.
35. Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol. 2009;83:1312–1319.
36. Letendre S, Paulino AD, Rockenstein E, et al.. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007;196:361–370.
37. Forton DM, Hamilton G, Allsop JM, et al.. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol. 2008;49:316–322.
38. Grover VP, Pavese N, Koh SB, et al.. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat. 2012;19:e89–e96.
HIV; Hepatitis C virus; neuropsychological test
Supplemental Digital Content
© 2013 Lippincott Williams & Wilkins, Inc.